Raymond James & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $86.2M | Buy |
82,006
+7,778
| +10% | +$8.66M | 0.05% | 305 |
|
|
2024
Q2 | $78M | Buy |
74,228
+2,887
| +4% | +$2.8M | 0.05% | 302 |
|
|
2024
Q1 | $68.7M | Buy |
71,341
+4,342
| +6% | +$4.13M | 0.05% | 337 |
|
|
2023
Q4 | $58.8M | Buy |
66,999
+5,499
| +9% | +$4.53M | 0.04% | 341 |
|
|
2023
Q3 | $50.6M | Sell |
61,500
-12
| -0% | -$9.43K | 0.04% | 347 |
|
|
2023
Q2 | $44.2M | Sell |
61,512
-564
| -0.9% | -$435K | 0.04% | 394 |
|
|
2023
Q1 | $51M | Buy |
62,076
+809
| +1% | +$610K | 0.04% | 349 |
|
|
2022
Q4 | $44.2M | Sell |
61,267
-5,318
| -8% | -$3.92M | 0.04% | 382 |
|
|
2022
Q3 | $45.9M | Sell |
66,585
-1,120
| -2% | -$705K | 0.05% | 338 |
|
|
2022
Q2 | $40M | Sell |
67,705
-21,860
| -24% | -$14.2M | 0.04% | 371 |
|
|
2022
Q1 | $62.6M | Sell |
89,565
-2,454
| -3% | -$1.55M | 0.05% | 302 |
|
|
2021
Q4 | $58.1M | Sell |
92,019
-4,256
| -4% | -$2.62M | 0.05% | 339 |
|
|
2021
Q3 | $58.3M | Sell |
96,275
-4,908
| -5% | -$3.05M | 0.05% | 307 |
|
|
2021
Q2 | $56.5M | Buy |
101,183
+9,986
| +11% | +$5.06M | 0.05% | 314 |
|
|
2021
Q1 | $43.1M | Sell |
91,197
-3,453
| -4% | -$1.68M | 0.04% | 361 |
|
|
2020
Q4 | $45.7M | Buy |
94,650
+614
| +0.7% | +$331K | 0.05% | 313 |
|
|
2020
Q3 | $52.6M | Sell |
94,036
-2,649
| -3% | -$1.61M | 0.07% | 249 |
|
|
2020
Q2 | $60.3M | Buy |
96,685
+12,733
| +15% | +$7.23M | 0.08% | 205 |
|
|
2020
Q1 | $41M | Buy |
83,952
+12,340
| +17% | +$5.09M | 0.07% | 243 |
|
|
2019
Q4 | $26.9M | Buy |
71,612
+3,024
| +4% | +$1.02M | 0.03% | 455 |
|
|
2019
Q3 | $19M | Buy |
68,588
+11,706
| +21% | +$3.46M | 0.03% | 564 |
|
|
2019
Q2 | $17.8M | Buy |
56,882
+3,049
| +6% | +$1.02M | 0.03% | 579 |
|
|
2019
Q1 | $22.1M | Sell |
53,833
-17,962
| -25% | -$7.4M | 0.03% | 484 |
|
|
2018
Q4 | $26.8M | Sell |
71,795
-10,267
| -13% | -$3.76M | 0.05% | 360 |
|
|
2018
Q3 | $33.2M | Buy |
82,062
+146
| +0.2% | +$55.6K | 0.05% | 350 |
|
|
2018
Q2 | $28.3M | Buy |
81,916
+29,864
| +57% | +$9.34M | 0.05% | 375 |
|
|
2018
Q1 | $17.9M | Buy |
52,052
+10,615
| +26% | +$3.69M | 0.03% | 520 |
|
|
2017
Q4 | $15.6M | Sell |
41,437
-3,053
| -7% | -$1.24M | 0.03% | 567 |
|
|
2017
Q3 | $19.9M | Buy |
44,490
+2,059
| +5% | +$980K | 0.04% | 452 |
|
|
2017
Q2 | $20.8M | Buy |
42,431
+3,798
| +10% | +$1.66M | 0.05% | 414 |
|
|
2017
Q1 | $15M | Buy |
38,633
+7,134
| +23% | +$2.64M | 0.03% | 510 |
|
|
2016
Q4 | $11.6M | Buy |
31,499
+6,280
| +25% | +$2.39M | 0.03% | 567 |
|
|
2016
Q3 | $10.1M | Buy |
25,219
+9,593
| +61% | +$3.85M | 0.03% | 603 |
|
|
2016
Q2 | $5.46M | Buy |
15,626
+1,428
| +10% | +$550K | 0.02% | 808 |
|
|
2016
Q1 | $5.12M | Sell |
14,198
-4,730
| -25% | -$1.95M | 0.02% | 810 |
|
|
2015
Q4 | $10.3M | Buy |
18,928
+5,026
| +36% | +$2.72M | 0.04% | 509 |
|
|
2015
Q3 | $6.47M | Sell |
13,902
-1,249
| -8% | -$671K | 0.03% | 636 |
|
|
2015
Q2 | $7.73M | Buy |
+15,151
| New | +$7.39M | 0.03% | 615 |
|
Other funds holding REGN
Raymond James & Associates's REGN Position: Q3 2024 in Review
Raymond James & Associates increased its Regeneron Pharmaceuticals (REGN) stake by 10% in Q3 2024, buying an estimated $8.66M and bringing the position to 82,006 shares worth $86.2M. The position accounts for 0.05% of the portfolio, ranked #305.
Raymond James & Associates first reported a position in REGN in Q2 2015 and has held it in 38 quarters since. 1,389 funds tracked by Wall St. Rank hold REGN as of Q3 2024.
- Raymond James & Associates held 82,006 shares of Regeneron Pharmaceuticals worth $86.2M as of Q3 2024.
- Raymond James & Associates bought 7,778 Regeneron Pharmaceuticals shares in Q3 2024, an estimated $8.66M.
- Regeneron Pharmaceuticals made up 0.05% of Raymond James & Associates's portfolio in Q3 2024, its #305 holding.
- Raymond James & Associates first reported a position in Regeneron Pharmaceuticals in Q2 2015 and has held it in 38 quarters since.
- 1,389 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2024.
Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.